

NEUREN PHARMACEUTICALS LIMITED

ANNUAL GENERAL MEETING
Tuesday, 27 May, 2025

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	<i>For</i>	<i>Against</i>	<i>Discretionary (OpenVotes)</i>	<i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>	<i>Result</i>
1	RE-ELECTION OF DIANNE ANGUS AS A DIRECTOR	NA	40,846,621 98.48%	455,727 1.10%	175,895 0.42%	3,797,500	41,837,988 98.92%	455,727 1.08%	3,797,500	Carried
2	RE-ELECTION OF JENNY HARRY AS A DIRECTOR	NA	40,763,607 98.28%	534,571 1.29%	179,595 0.43%	3,797,970	41,758,674 98.74%	534,571 1.26%	3,797,970	Carried
3	AUDITOR FEES AND EXPENSES	NA	45,077,851 99.60%	6,116 0.01%	176,298 0.39%	15,478	46,069,621 99.99%	6,116 0.01%	15,478	Carried
4	INCREASE TO NON-EXECUTIVE DIRECTOR FEE POOL	NA	44,351,938 98.14%	703,180 1.56%	139,693 0.31%	40,932	45,292,603 98.47%	703,180 1.53%	40,932	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item